Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview

1127studies shown

Showing 951-975 of 1,127

OngoingEUCTR 2018-001884-21

A randomised, placebo-controlled, double-blind trial of the antidepressant efficacy of a novel CNS-penetrant P2X7 receptor antagonist, JNJ-54175446, in people with major depressive disorder, an inc...

This study is comparing JNJ-54175446 with placebo for people with depression with an incomplete response to monoaminergic antidepressants and with biomarker profile indicative of inflammation. Participants receive JNJ-54175446 or placebo and complete study visits and assessments.

DepressionOther

Countries: United Kingdom, View results
Sponsor: Cambridgeshire and Peterborough NHS Foundation Trust and University of Cambridge
Condition: Depression

OngoingEUCTR 2014-004937-15

A randomized, double-blinded, placebo and lorazepam-controlled, four-way crossover, Phase II study to evaluate the effects of single oral administration of BNC210 on brain activity changes captured...

This study is looking at care and outcomes for people with Generalized anxiety. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.

AnxietyOther

Countries: United Kingdom
Sponsor: BIONOMICS LIMITED
Condition: Anxiety

OngoingEUCTR 2018-003252-20

A 52-Week Open-Label Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

This study is looking at whether Pimavanserin can help people with depression or Elderly. Participants receive the study medicine Pimavanserin and complete study visits and assessments.

DepressionOther

Countries: United Kingdom, Slovakia, Poland, Finland, View results
Sponsor: ACADIA Pharmaceuticals Inc
Condition: Depression

OngoingEUCTR 2017-003288-36

The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression (P-TRD)

This study is looking at whether PSILOCYBIN can help people with Treatment-Resistant Depression or Elderly. Participants receive the study medicine PSILOCYBIN and complete study visits and assessments.

DepressionOther

Countries: United Kingdom, Czech Republic, Germany, Portugal, Netherlands, Ireland, Denmark, Spain, View results
Sponsor: COMPASS Pathways, Ltd
Condition: Depression

CompletedEUCTR 2018-002782-19

A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS AN ADJUNCT TO ANTIDEPRESSANTS IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER WHO HAVE HAD AN INADEQUATE RESPONSE TO ANTIDEPRE...

This study is comparing Cariprazine with placebo for people with depression or Elderly. Participants receive Cariprazine or placebo and complete study visits and assessments.

DepressionOther

Countries: Germany, Hungary, Bulgaria, United Kingdom, View results
Sponsor: Allergan Ltd.
Condition: Depression

CompletedEUCTR 2020-000341-14

A Double-Blind, Randomized, Parallel-Group Study with Quetiapine Extended Release as Comparator to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in ...

This study is comparing Seltorexant with quetiapine for people with depression or Elderly. Participants receive Seltorexant or quetiapine and complete study visits and assessments.

DepressionOther

Countries: Czech Republic, United Kingdom, Lithuania, Latvia, Belgium, Bulgaria, Poland, Slovakia, View results
Sponsor: Janssen-Cilag International NV
Condition: Depression

OngoingEUCTR 2017-001170-42

An adaptive Phase II/III, Double-Blind, Randomized, Placebo-controlled, Two-Part, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen® (sodium benzoate), a D-Amino Acid Oxidase In...

This study is comparing SODIUM BENZOATE with placebo for people with Treatment for Refractory Schizophrenia in. Participants receive SODIUM BENZOATE or placebo and complete study visits and assessments.

SchizophreniaOther

Countries: Germany, United Kingdom, Poland
Sponsor: SyneuRx International (Taiwan) Corp
Condition: Schizophrenia

CompletedEUCTR 2008-005353-38

Interventional, randomised, double-blind, placebo-controlled, active reference (fluoxetine), fixed-dose study of vortioxetine in paediatric patients aged 7 to 11 years, with Major depressive disord...

This study is comparing VORTIOXETINE with Fluoxetine for people with depression or Children, Under 18. Participants receive VORTIOXETINE or Fluoxetine and complete study visits and assessments.

DepressionOther

Countries: Latvia, Estonia, United Kingdom, Hungary, Finland, Germany, Italy, Spain, Bulgaria, Poland, France, View results
Sponsor: H. Lundbeck A/S
Condition: Depression

CompletedEUCTR 2017-001168-39

An Adaptive, Phase IIb/III, Double-Blind, Randomized, Placebo- Controlled, Multi-Center Study of the Safety and Efficacy of NaBen® (sodium benzoate), a D-Amino Acid Oxidase Inhibitor, as an Add-on ...

This study is comparing SODIUM BENZOATE with placebo for people with Treatment for Schizophrenia in Adolescents or Adolescents, Under 18. Participants receive SODIUM BENZOATE or placebo and complete study visits and assessments.

SchizophreniaOther

Countries: Poland, United Kingdom
Sponsor: SyneuRx International (Taiwan) Corp
Condition: Schizophrenia

OngoingEUCTR 2017-001169-26

An Adaptive, Phase IIb/III, Multi-center, Prospective, Randomized, Double-Blind Placebo-controlled Study of the Safety and Efficacy of NaBen® (sodium benzoate), a D-Amino Acid Oxidase Inhibitor, as...

This study is comparing SODIUM BENZOATE with placebo for people with Treatment for Schizophrenia in. Participants receive SODIUM BENZOATE or placebo and complete study visits and assessments.

SchizophreniaOther

Countries: United Kingdom, Poland
Sponsor: SyneuRx International (Taiwan) Corp
Condition: Schizophrenia

CompletedEUCTR 2015-003578-34

An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment resistant Depression

This study is looking at whether ESKETAMINE Esketamine (for (S)-2-(o-chlorophenyl)-2-(methylamino)cyclohexanone) can help people with Treatment-resistant Major Depression or Elderly. Participants receive the study medicine ESKETAMINE Esketamine (for (S)-2-(o-chlorophenyl)-2-(methylamino)cyclohexanone) and complete study visits and assessments.

DepressionOther

Countries: Germany, United Kingdom, Belgium, Spain, Poland, Hungary, Czech Republic, Slovakia, Lithuania, Austria, Finland, Bulgaria, Italy, View results
Sponsor: Janssen-Cilag International NV
Condition: Depression

OngoingEUCTR 2018-000821-29

A Phase 4, Multicenter, 2-part Study Composed of a 1-Year Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation followed by a 1-Year Open-lab...

This study is comparing GUANFACINE HYDROCHLORIDE with ATOMOXETINE HYDROCHLORIDE for people with Attention-deficit/hyperactivity disorder or Children, Adolescents, Under 18. Participants receive GUANFACINE HYDROCHLORIDE or ATOMOXETINE HYDROCHLORIDE and complete study visits and assessments.

ADHDOther

Countries: Germany, Netherlands, Sweden, Austria, Spain, Belgium, Portugal, United Kingdom
Sponsor: Takeda Development Center Americas, Inc.
Condition: ADHD

OngoingEUCTR 2012-001779-35

The effects of pregabalin augmentation of antidepressant drug on neuro-cognitive functioning in patients with generalized anxiety disorder

This study is looking at whether Lyrica can help people with Generalised anxiety. Participants receive the study medicine Lyrica and complete study visits and assessments.

AnxietyOther

Countries: United Kingdom
Sponsor: University of Southampton
Condition: Anxiety

OngoingEUCTR 2015-003542-68

The effect of single-dose losartan on the basic effects of cognitive-behaviour therapy for panic disorder - a randomized double blind placebo-controlled trial

This study is comparing losartan with placebo for people with DSM panic disorder or Elderly. Participants receive losartan or placebo and complete study visits and assessments.

AnxietyOther

Countries: United Kingdom
Sponsor: University of Oxford
Condition: Anxiety

OngoingEUCTR 2019-001408-39

Treating Anxiety to PrevEnt Relapse in Psychosis (TAPERS): a feasibility trial

This study is comparing sertraline hydrochloride with placebo for people with Psychosis. Participants receive sertraline hydrochloride or placebo and complete study visits and assessments.

SchizophreniaOther

Countries: United Kingdom, View results
Sponsor: Cardiff University
Condition: Schizophrenia

OngoingEUCTR 2018-002740-82

A phase II randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily with adjunctive Computerized Cognitive Training over 12 wee...

This study is looking at care and outcomes for people with schizophrenia. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.

SchizophreniaOther

Countries: United Kingdom, View results
Sponsor: Boehringer Ingelheim Limited
Condition: Schizophrenia

OngoingEUCTR 2016-000709-36

Research into Antipsychotic Discontinuation and Reduction (RADAR): A Randomised Controlled Trial

This study is looking at care and outcomes for people with Schizophrenia, delusional disorders, schizoaffective disorder, psychosis or Elderly. Direct benefit is not guaranteed, but the study may help researchers improve future care.

SchizophreniaOther

Countries: United Kingdom, View results
Sponsor: UCL
Condition: Schizophrenia

OngoingEUCTR 2017-001739-38

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate Pharmacodynamic Effects, Safety, Tolerability, and pharmacokinetics of Multiple Oral Doses of TAK-831 in Adult...

This study is comparing TAK-831 with placebo for people with Schizophrenia. Participants receive TAK-831 or placebo and complete study visits and assessments.

SchizophreniaOther

Countries: United Kingdom, View results
Sponsor: Takeda Development Centre Europe Ltd.
Condition: Schizophrenia

OngoingEUCTR 2017-004064-35

Liraglutide and the management of overweight and obesity in people with schizophrenia: a pilot study

This study is comparing LIRAGLUTIDE with placebo for people with Schizophrenia, schizoaffective disorder or first episode psychosis or Elderly. Participants receive LIRAGLUTIDE or placebo and complete study visits and assessments.

SchizophreniaOther

Countries: United Kingdom
Sponsor: Southern Health NHS Foundation Trust
Condition: Schizophrenia

CompletedEUCTR 2018-003825-27

A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BIIB104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)

This study is comparing BIIB104 with placebo for people with Schizophrenia. Participants receive BIIB104 or placebo and complete study visits and assessments.

SchizophreniaOther

Countries: Germany, United Kingdom, View results
Sponsor: Biogen Idec Research Limited
Condition: Schizophrenia

OngoingEUCTR 2016-004973-42

A phase II randomised, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered BI 409306 during a 52-week treatment period as an early inter...

This study is looking at care and outcomes for people with attenuated psychosis syndrome or Adolescents, Under 18. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.

SchizophreniaOther

Countries: United Kingdom, View results
Sponsor: Boehringer Ingelheim Limited
Condition: Schizophrenia

OngoingEUCTR 2016-000118-31

A randomised phase II double-blinded placebo-controlled trial of intravenous immunoglobulins and rituximab in patients with antibody-associated psychosis (SINAPPS2)

This study is comparing Human normal immunoglobulin with placebo for people with Antibody associated Psychosis or Elderly. Participants receive Human normal immunoglobulin or placebo and complete study visits and assessments.

SchizophreniaOther

Countries: United Kingdom
Sponsor: Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge
Condition: Schizophrenia

OngoingEUCTR 2019-003623-37

CANnabidiol for Parkinson’s Disease Psychosis

This study is comparing Cannabidiol (CBD) with placebo for people with Parkinson's disease psychosis or Elderly. Participants receive Cannabidiol (CBD) or placebo and complete study visits and assessments.

SchizophreniaOther

Countries: United Kingdom
Sponsor: King's College London [...] 1. King's College London 2. South London and Maudsley NHS Foundation Trust
Condition: Schizophrenia

CompletedEUCTR 2015-003503-39

Placebo-controlled Trial in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe

This study is looking at care and outcomes for people with Individuals at Ultra High Risk for Psychosis or Adolescents, Under 18. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.

SchizophreniaOther

Countries: Netherlands, Austria, Italy, Spain, Germany, United Kingdom
Sponsor: University Medical Center Utrecht
Condition: Schizophrenia

OngoingEUCTR 2017-002227-13

A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated With Dementia-related Psychosis

This study is comparing Pimavanserin with placebo for people with Hallucinations and Delusions Associated With Dementia-related Psychosis or Elderly. Participants receive Pimavanserin or placebo and complete study visits and assessments.

SchizophreniaOther

Countries: United Kingdom, Czech Republic, Slovakia, Bulgaria, Spain, Poland, France, Italy, View results
Sponsor: ACADIA Pharmaceuticals Inc.
Condition: Schizophrenia